Financial & Tax Architects LLC Acquires 1,525 Shares of Sanofi (NASDAQ:SNY)

Financial & Tax Architects LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 14.8% in the fourth quarter, HoldingsChannel reports. The firm owned 11,824 shares of the company’s stock after purchasing an additional 1,525 shares during the period. Financial & Tax Architects LLC’s holdings in Sanofi were worth $570,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SNY. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the period. Franklin Resources Inc. grew its stake in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Natixis Advisors LLC grew its stake in Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares during the period. Raymond James & Associates grew its stake in Sanofi by 4.8% in the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock valued at $162,479,000 after acquiring an additional 129,472 shares during the period. Finally, Magnetar Financial LLC grew its stake in Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

SNY stock remained flat at $50.74 during midday trading on Friday. The company’s stock had a trading volume of 2,426,236 shares, compared to its average volume of 2,173,288. The company’s 50-day moving average is $48.46 and its 200-day moving average is $52.09. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a market cap of $128.77 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.17 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the firm earned $2.55 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts forecast that Sanofi will post 3.94 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.